Acer Therapeutics Regained the Development and Commercialization Rights for Olpruva from Relief Therapeutics for Areas Excluding Geographical Europe
Shots:
- Post termination, Relief will receive an up front payment of $10M and an additional $1.5M. Moreover, Acer will pay Relief a 10% royalty on net sales of Olpruva in the Acer regions (US, Canada, Brazil, Turkey & Japan) & 20% of any value it receives from specified third parties in connection with Olpruva licensing or divestment rights
- Acer & Relief have signed an Exclusive License Agreement under which Relief will retain the development & commercialization rights for Olpruva across Geographical Europe for which Acer will receive a 10% royalty on net sales
- Earlier, Acer owed Relief 60% of the net sales of Olpruva in the Acer regions while receiving a 15% royalty on Relief's net sales in the rest of the world
Ref: GlobeNewswire | Image: Acer
Related News:- Acer Therapeutics and Relief Therapeutics Receive the US FDA’s Approval of Olpruva for Urea Cycle Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
